Friday, May 08, 2015 10:56:26 AM
Doesn't mean that the insiders (being insiders after all) don't know something that we all don't know as yet.
I suspect that the favorable analysts reviews are due to a combination of publically known factors that include:
1) The fact that HEB's drug was apparently extremely effective against Ebola virus in mouse models when tested this last Winter.
2) The investments that the company has been making in upgrading their Alferon manufacturing facility, that 'should' lead to the facility being much more cost-effective and efficient at producing Alferon sometime in the next 9-12 months.
3) The experimental data (even though the FDA hasn't greenlighted it yet) that suggests that - at least for some patients - Ampligen can provide relief from Chronic Fatigue Syndrome.
But these are just guesses, and mostly are spelled out in the Arrowhead analysis document - so hard to know if the insiders know something else that we don't know (yet).
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM